Under construction – not a live service
Sign in
Not yet taking people in PakistanNo phase

Pharmacist Education Through Telemedicine for People With Asthma

Tests pharmacist-led education by telemedicine in people with asthma aged 11 or older.

Plain-language title generated from the registry record
Registry title: Asthma Control Through Telemedicine

Key facts

Where
Islamabad, PakistanSee the site

Where in Pakistan

  • Hamdard UniversityIslamabad, PakistanNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Hamdard University
Trial code
NCT06863285
Record updated
11 March 2025
Original description
The purpose of this research study is to evaluate the impact of pharmacist led educational interventions on Asthmatic patients, and also determine their medication adherence.Read full original descriptionShow less

The Pharmacist Led Educational Interventions Through Telemedicine to Improve Asthma Control: a Randomized Control Trial

The purpose of this research study is to evaluate the impact of pharmacist led educational interventions on Asthmatic patients, and also determine their medication adherence.

Pharmacist's intervention aims to answer:

1. How a pharmacist intervention program impact medication adherence in persistent asthma? 2. To assess how pharmacist led educational intervention like patients' counseling and medication reminders through Telemedicine have an impact on patient's asthma control? 3. Which mode of communication (Verbal instructions, videos and pamphlets) for the patient counselling is most beneficial for the patients in asthma control.

Inclusion: Age above 11 years; Persistent Asthma Patient; Patients taking medications and inhaler; Patient who will consent for the study; Patient with basic telecommunication facility; Patient who responded to messages and calls.

Exclusion: Patients who will refuse to participate in study will not be included; Irresponsive patients to messages and calls.

ClinicalTrials.gov NCT06863285